- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diagnosis of Intestinal Parasites
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antidepressants, With Confirmation, Urine
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Hepatitis B Surface Antigen, Quantitative, MonitoringTest code(s) 94333
Question 1. What is the clinical utility of quantitative hepatitis B virus (HBV) surface antigen (HBsAg) testing?
Quantitation of HBsAg may be helpful in differentiating phases of HBV infection, evaluating prognosis (to date, most data has been for patients with hepatitis B envelope antigen [HBeAg]-negative genotype B or C infection), monitoring response to treatment with pegylated interferon (peg-IFN) or nucleos(t)ide analogs (NAs), and guiding decisions on treatment duration.
Question 2. How is quantitative different from qualitative HBsAg testing?
Qualitative HBsAg testing is recommended to screen patients at risk for HBV infection and is the test recommended for initial diagnosis. It may also be useful to determine vaccine responses for selected patients. In contrast, quantitative HBsAg testing is not recommended for initial diagnosis, but it is useful for disease and treatment monitoring (see Question 1).
Question 3. HBV DNA levels represent active replication of the virus. What do HBsAg levels represent?
Serum HBsAg levels reflect the transcriptional activity of intrahepatic HBV covalently closed circular DNA (cccDNA), an indicator of viral protein synthesis.
Question 4. What are the phases of chronic HBV infection, and how is laboratory testing used to help differentiate them?
Phases of HBV infection are 1) immune-tolerant, 2) immune-active, 3) inactive chronic (inactive carrier), 4) immune-escape (HBeAg-negative chronic), and 5) reactivation. Alanine aminotransferase (ALT) and HBV DNA levels can be helpful in differentiating the phases of HBV infection:
- Immune-tolerant phase: ALT levels are normal; HBV DNA levels are high.
- Immune-active phase: ALT levels can be high or intermittently high; HBV DNA levels can fluctuate.
- Inactive chronic hepatitis (inactive carrier) phase: ALT levels are normal and HBV DNA levels are low or undetectable.
- Immune-escape phase (HBeAg-negative chronic hepatitis): ALT levels are elevated or may fluctuate; HBV levels tend to be moderate or high.
- Reactivation phase: ALT levels are elevated; HBV levels tend to be moderate or high.
However, because of the overlap in ALT and HBV DNA patterns between phases, these markers are not sufficient to identify the exact phase of disease.13 Analysis of multiple markers of HBV infection will be helpful in determining disease phase and potential treatment options. Quantitative HBsAg determination and HBeAg status may be additional markers that can be useful for prognosis and therapeutic decision-making in patients with different phases of infection. For example, HBeAg-negative patients with low HBV DNA (<2000 IU/mL), low HBsAg (<1000 IU/mL), and selected genotypes may be considered to be in the inactive carrier state.2 Low serum HBsAg levels measured 1 year after documented HBeAg seroconversion may predict subsequent HBsAg loss in genotype B or C infection.5 Conversely, lack of HBsAg decline and modest (<2 log) reduction in HBV DNA after the third month of antiviral treatment has been suggested as a stopping rule in HBeAg-negative patients with genotype D. 6,7 Like HBV DNA levels, HBsAg and HBeAg levels are typically highest in the immune-tolerant phase, decline in the immune-active phase, and are generally lowest in the inactive carrier phase.
Question 5. How can quantitative HBsAg levels help distinguish the different phases of HBV infection?
Quantitative HBsAg results, along with selected immunologic and virologic characteristics, may help differentiate infection phases and inform prognosis and therapeutic decision-making. For example, the HBeAg-negative inactive carrier state may be identified by low HBV DNA (<2000 IU/mL) and low HBsAg (<1000 IU/mL) in patients with certain genotypes.2 Low serum HBsAg levels measured 1 year after documented HBeAg seroconversion may predict subsequent HBsAg loss in HBV genotype B or C infection.5 It has been documented that a drop in HBsAg levels in patients who are on NA treatment can predict subsequent HBsAg loss. The observed decrease in HBsAg concentration may help predict HBsAg loss and support the decision to discontinue peg-IFN and/or NA therapy.
Peg-interferon and/or NA treatment may lead to reductions in HBsAg. In general, sustained responders display greater and/or more rapid HBsAg decline than non-responders.1-2,4-6 The quantitative HBsAg level that best predicts sustained virologic response (or “cure”) has yet to be well established. However, some experts consider 2 or more measurements of HBsAg below the assay’s lower limit of detection (<0.05 IU/mL) obtained ≥6 months apart to be a potentially useful endpoint for antiviral therapy.9-11
Question 6. How do lower limits of detection compare between quantitative HBsAg and qualitative HBsAg testing?
Overall, there is close agreement between the two assays. They have similar lower limits of detection: 0.085 IU/mL for qualitative HBsAg and 0.05 IU/mL for quantitative HBsAg.
Question 7. Does serum HBsAg quantitation replace the need for quantitative HBV DNA measurement?
No. For most patients, both tests are needed to monitor chronic HBV infection status and response to therapy. Lacking further data, quantitative HBsAg may be used in conjunction with HBV DNA monitoring and other appropriate laboratory testing.1
Question 8. How should discordant results for HBV DNA and HBsAg quantitation be handled?
Published data show some concordance between these 2 assays in individual patients. However, some patients have high levels of HBsAg but decreasing, low, or undetectable HBV DNA. This discordance may be related to differences in disease phase: HBsAg levels can be high because of active transcription of cccDNA, while HBV DNA levels decrease or become undetectable because of decreasing DNA replication. Therefore, measurement of both HBsAg and HBV DNA can provide a more accurate clinical profile for an individual patient and help monitor and predict treatment outcomes. The information gained with both results, even if discordant, can provide additional insights into the patient’s prognosis.
Question 9. Which method is used to determine quantitative HBsAg levels?
Quest Diagnostics uses an immunoassay method for quantitative HBsAg testing. The method employs the Ortho Vitros® system to construct a standard curve for the quantitative result calculation. The WHO 3rd International standard reference serum (HBV genotype B4, HBsAg subtypes ayw1/adw2) was used to verify the values established for the calibration standard. Results are reported in IU/mL.
- Wong G, Chan H. Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. Clin Liver Dis. 2013;2:8-10.
- Henry Lik-Yuen Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. J Hepatol. 2011;55:1121–1131.
- Edouard Tuaillon , Anne-Marie Mondain, Nicolas Nagot, et al. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One. 2012;7:e32143.
- Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology. 2009;49:S166–S173.
- Tseng T, Liu C, Su T, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141:517–525.
- Kranidiotia H, Manolakopoulosb S, Khakooa SI. Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. Ann Gastroenterol. 2015;28:173-181.
- Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53:1486-1493.
- Centers for Disease Control and Prevention. Hepatitis B, chronic 2012 case definition. https://wwwn.cdc.gov/nndss/conditions/hepatitis-b-chronic/case-definition/2012/. Accessed November 3, 2016.
- Sonneveld MJ, Rijckborst V, Boucher C, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010; 52: 1251–1257.
- Seth AK. HBsAg quantification in clinical practice. J Clin Exp Hepatol. 2012;2:75-80.
- Sarin S, Kumar M, Lau G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
- Höner Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol. 2014;27:105-112.
- World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: WHO; 2015. http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1. Accessed June 6, 2017.